Related Experiment Video
Updated: Oct 15, 2025

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Calcification Propensity in Serum and Cardiovascular Outcome in Peripheral Artery Disease
Marija Bojic1, Bernhard Bielesz1, Daniel Cejka2
1Division of Nephrology, Medicine III, Medical University of Vienna, Austria.
Insights
The T50 test measures serum calcification propensity. Lower T50 values, indicating higher calcification propensity, are linked to major adverse cardiovascular events and cardiovascular mortality in peripheral artery disease patients.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Biochemistry
Background:
- Peripheral artery disease (PAD) is associated with increased cardiovascular risk.
- Serum calcification propensity, measured by the T50 test, is a novel biomarker linked to cardiovascular events and mortality in various populations.
- The role of calcification propensity in PAD patients without severe chronic kidney disease (CKD) requires further investigation.
Purpose of the Study:
- To investigate the association between serum calcification propensity (T50 test) and major adverse cardiovascular events (MACE+) and mortality in patients with PAD.
- To assess the predictive value of T50 test for cardiovascular outcomes in a cohort of PAD patients without severe CKD.
Main Methods:
- A cohort of 287 patients with PAD without severe CKD was studied.
- Serum calcification propensity was measured using the T50 test.
- Major cardiovascular events (MACE+) and all-cause death were evaluated over a median follow-up of 4 years, and long-term mortality over 8.7 years.
- Kaplan-Meier and Cox regression analyses were used to assess associations, with adjustments for cardiovascular risk factors (CVRFs), PAD stage, and media sclerosis.
Main Results:
- Mean T50 time was 268 ± 63 minutes.
- Low T50 values (high calcification propensity) were significantly associated with MACE+ (HR: 0.72; 95% CI: 0.55-0.94), an association that persisted after multivariate adjustment (HR: 0.65; CI: 0.47-0.91).
- Cardiovascular mortality was significantly associated with T50 after multivariate adjustment (HR: 0.72; CI: 0.53-0.99), but all-cause mortality was not.
Conclusions:
- Serum calcification propensity, as measured by the T50 test, is associated with an increased risk of major adverse cardiovascular events in patients with PAD.
- The T50 test may serve as a valuable prognostic biomarker for cardiovascular mortality in PAD patients.
- These findings highlight the importance of assessing calcification propensity in PAD management.
Abstract:
Peripheral artery disease (PAD) has been shown to be linked to elevated cardiovascular risk. The novel T50 test quantifies calcification propensity of serum and has been associated with cardiovascular events and mortality in patients with chronic kidney disease (CKD) and in the general population. This study investigated the association of calcification propensity measured by the T50 test in 287 patients with PAD without severe CKD. Major cardiovascular events (MACEs) including nonfatal stroke and nonfatal myocardial infarction and all-cause death (MACE + ) were evaluated after a median follow-up of 4 years and long-term cardiovascular and all-cause mortality after a median follow-up of 8.7 years by Kaplan-Meier and Cox regression analyses. Mean T50 time was 268 ± 63 minutes in the study cohort (age 69 ± 10 years, 32% women, 47% diabetes). Low T50 values that signify high calcification propensity were significantly associated with the occurrence of MACE+ (hazard ratio [HR]: 0.72; 95% confidence interval [CI]: 0.55-0.94). This association sustained multivariate adjustment for cardiovascular risk factors (CVRFs), Fontaine PAD stage, and prevalent media sclerosis (HR: 0.65; CI: 0.47-0.91). Cardiovascular mortality was significantly associated with T50 after multivariate adjustment for CVRF (HR: 0.72; CI 0.53-0.99), but not all-cause mortality (HR: 0.80; CI: 0.64-1.01). In conclusion, calcification propensity associates with MACE+ and cardiovascular mortality in patients with PAD.
Related Concept Videos
Peripheral Artery Disease I: Introduction
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology

